HESI ITC Immunosafety Training Course
Introduction Module

HESI : Human health and Safety
Dr. Syril Pettit - HESI

Safety assessment outside of drug development (e.g. agrichemicals, cosmetics, food additives, etc.)
Dr. Vick Johnson - Burleson Research Technologies Lab

Basic principles of toxicology, toxicology of the immune system, relevance to immunosafety
Dr. Marc Pallardy - Universite-Paris-Saclay

Basic immunology: cells, innate and adaptive immunity
Dr. Wendy Jo Freebern - Janssen

Basic immunology: complement and hypersensitivies
Dr. Marc Pallardy - Universite-Paris-Saclay

Immunomodulating therapies (overview)
Dr. Marie-Soleil Piche - Charles River Laboratory

Immuno-oncology
Dr. Birgit Fogal - Boehringer-Ingelheim

T cell targeting therapies (e.g. activation, inhibition pathways, therapies, toxicities)
Dr. Courtni Newsome - Bristol-Myers Squibb

B cell targeting therapies (e.g. activation, inhibition pathways, therapies, toxicities)
Dr. Marta Fernandez - Janssen

Innate immune cell therapies (e.g. activation, inhibition pathways, therapies, toxicities)
Dr. Rashade Haynes - Bristol-Myers Squibb

Immunopathology: evaluation, assessment, and considerations
Dr. Tracey Papenfuss - Charles River Laboratory

Assessing adversity in immunosafety (preclinical)
Dr. Tracey Papenfuss - Charles River Laboratory

Immune-related adverse events (clinical)
Dr.Robert Hseia - Genentech

Animal models and species differences (immune system)
Dr. Ashwini Phadnis - Moghe-Bluebird Bio

Translational biology and immunology: translatability, challenges
Dr. Ana Goyos - Janssen

Diversity of immune responses (impact of age, sex, pregnancy, co-morbidities, etc.)
Dr. April Masters - Boehringer- Ingelheim

Regulatory guidance: Introduction
Dr. Dave McMillan - US FDA

The field and study of immunosafety is a rapidly evolving area important for the evaluating the relative safety of new drugs, therapies, and environmental agents that affect the immune system and determine risk to human health. There has been an ever-increasing number of such therapies that specifically target the immune system and the ways that various therapies impact and modulate the immune system (whether on-target or off-target) have become increasingly nuanced. Such complex immunomodulatory effects require that scientists become increasingly knowledgeable about the cells, signaling pathways, and overall function of the immune system. This Immuosafety introduction module is design to acquaint audience with foundational aspects in immune safety science by providing "lighting talks" on key concepts, presented by recognized experts in the field.